298 related articles for article (PubMed ID: 18036235)
21. Nuclear Exclusion of the HIV-1 host defense factor APOBEC3G requires a novel cytoplasmic retention signal and is not dependent on RNA binding.
Bennett RP; Presnyak V; Wedekind JE; Smith HC
J Biol Chem; 2008 Mar; 283(12):7320-7. PubMed ID: 18165230
[TBL] [Abstract][Full Text] [Related]
22. The level of APOBEC3G (hA3G)-related G-to-A mutations does not correlate with viral load in HIV type 1-infected individuals.
Ulenga NK; Sarr AD; Hamel D; Sankale JL; Mboup S; Kanki PJ
AIDS Res Hum Retroviruses; 2008 Oct; 24(10):1285-90. PubMed ID: 18851679
[TBL] [Abstract][Full Text] [Related]
23. ASK1 restores the antiviral activity of APOBEC3G by disrupting HIV-1 Vif-mediated counteraction.
Miyakawa K; Matsunaga S; Kanou K; Matsuzawa A; Morishita R; Kudoh A; Shindo K; Yokoyama M; Sato H; Kimura H; Tamura T; Yamamoto N; Ichijo H; Takaori-Kondo A; Ryo A
Nat Commun; 2015 Apr; 6():6945. PubMed ID: 25901786
[TBL] [Abstract][Full Text] [Related]
24. Induction of heat-shock protein 70 by prostaglandin A₁ inhibits HIV-1 Vif-mediated degradation of APOBEC3G.
Sugiyama R; Abe M; Nishitsuji H; Murakami Y; Takeuchi H; Takaku H
Antiviral Res; 2013 Sep; 99(3):307-11. PubMed ID: 23831493
[TBL] [Abstract][Full Text] [Related]
25. APOBEC3G and APOBEC3F Act in Concert To Extinguish HIV-1 Replication.
Krisko JF; Begum N; Baker CE; Foster JL; Garcia JV
J Virol; 2016 May; 90(9):4681-4695. PubMed ID: 26912618
[TBL] [Abstract][Full Text] [Related]
26. A novel HIV-1 inhibitor that blocks viral replication and rescues APOBEC3s by interrupting vif/CBFβ interaction.
Duan S; Wang S; Song Y; Gao N; Meng L; Gai Y; Zhang Y; Wang S; Wang C; Yu B; Wu J; Yu X
J Biol Chem; 2020 Oct; 295(43):14592-14605. PubMed ID: 32817167
[TBL] [Abstract][Full Text] [Related]
27. APOBEC3G subunits self-associate via the C-terminal deaminase domain.
Bennett RP; Salter JD; Liu X; Wedekind JE; Smith HC
J Biol Chem; 2008 Nov; 283(48):33329-36. PubMed ID: 18842592
[TBL] [Abstract][Full Text] [Related]
28. HIV-1 Vif blocks the antiviral activity of APOBEC3G by impairing both its translation and intracellular stability.
Stopak K; de Noronha C; Yonemoto W; Greene WC
Mol Cell; 2003 Sep; 12(3):591-601. PubMed ID: 14527406
[TBL] [Abstract][Full Text] [Related]
29. The antiretroviral enzyme APOBEC3G is degraded by the proteasome in response to HIV-1 Vif.
Sheehy AM; Gaddis NC; Malim MH
Nat Med; 2003 Nov; 9(11):1404-7. PubMed ID: 14528300
[TBL] [Abstract][Full Text] [Related]
30. APOBEC3G-UBA2 fusion as a potential strategy for stable expression of APOBEC3G and inhibition of HIV-1 replication.
Li L; Liang D; Li JY; Zhao RY
Retrovirology; 2008 Aug; 5():72. PubMed ID: 18680593
[TBL] [Abstract][Full Text] [Related]
31. Anti-APOBEC3G activity of HIV-1 Vif protein is attenuated in elite controllers.
Kikuchi T; Iwabu Y; Tada T; Kawana-Tachikawa A; Koga M; Hosoya N; Nomura S; Brumme ZL; Jessen H; Pereyra F; Trocha A; Walker BD; Iwamoto A; Tokunaga K; Miura T
J Virol; 2015 May; 89(9):4992-5001. PubMed ID: 25717111
[TBL] [Abstract][Full Text] [Related]
32. Evolution of HIV-1 isolates that use a novel Vif-independent mechanism to resist restriction by human APOBEC3G.
Haché G; Shindo K; Albin JS; Harris RS
Curr Biol; 2008 Jun; 18(11):819-24. PubMed ID: 18501607
[TBL] [Abstract][Full Text] [Related]
33. APOBEC3G-induced hypermutation of human immunodeficiency virus type-1 is typically a discrete "all or nothing" phenomenon.
Armitage AE; Deforche K; Chang CH; Wee E; Kramer B; Welch JJ; Gerstoft J; Fugger L; McMichael A; Rambaut A; Iversen AK
PLoS Genet; 2012; 8(3):e1002550. PubMed ID: 22457633
[TBL] [Abstract][Full Text] [Related]
34. [Progress in the study of HIV-1 Vif and related inhibitors].
Li ZY; Zhan P; Liu XY
Yao Xue Xue Bao; 2010 Jun; 45(6):684-93. PubMed ID: 20939174
[TBL] [Abstract][Full Text] [Related]
35. Mutational alteration of human immunodeficiency virus type 1 Vif allows for functional interaction with nonhuman primate APOBEC3G.
Schröfelbauer B; Senger T; Manning G; Landau NR
J Virol; 2006 Jun; 80(12):5984-91. PubMed ID: 16731937
[TBL] [Abstract][Full Text] [Related]
36. The human immunodeficiency virus type 1 Vif protein reduces intracellular expression and inhibits packaging of APOBEC3G (CEM15), a cellular inhibitor of virus infectivity.
Kao S; Khan MA; Miyagi E; Plishka R; Buckler-White A; Strebel K
J Virol; 2003 Nov; 77(21):11398-407. PubMed ID: 14557625
[TBL] [Abstract][Full Text] [Related]
37. The viral infectivity factor (Vif) of HIV-1 unveiled.
Rose KM; Marin M; Kozak SL; Kabat D
Trends Mol Med; 2004 Jun; 10(6):291-7. PubMed ID: 15177194
[TBL] [Abstract][Full Text] [Related]
38. Antiviral roles of APOBEC proteins against HIV-1 and suppression by Vif.
Romani B; Engelbrecht S; Glashoff RH
Arch Virol; 2009; 154(10):1579-88. PubMed ID: 19669862
[TBL] [Abstract][Full Text] [Related]
39. Inhibition of HIV-1 infection and replication by enhancing viral incorporation of innate anti-HIV-1 protein A3G: a non-pathogenic Nef mutant-based anti-HIV strategy.
Green LA; Liu Y; He JJ
J Biol Chem; 2009 May; 284(20):13363-13372. PubMed ID: 19324886
[TBL] [Abstract][Full Text] [Related]
40. Host AKT-mediated phosphorylation of HIV-1 accessory protein Vif potentiates infectivity via enhanced degradation of the restriction factor APOBEC3G.
Raja R; Wang C; Mishra R; Das A; Ali A; Banerjea AC
J Biol Chem; 2022 Apr; 298(4):101805. PubMed ID: 35259395
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]